Monopar Therapeutics Inc.

NASDAQ:MNPR

Biotechnology

Healthcare
$70.75 +2.45%

+$1.58 today

Market cap
$479.46M
Beta
1.54
P/E (TTM)
-37.6
EPS (TTM)
-$1.76
52W Low $29.18High $105.00

Volume 0.10M

Average 0.17M

MNPR Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Monopar Therapeutics Inc.NASDAQ: MNPR

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $1.74B rose 110009.0% year over year, ahead of the +43733.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 78396.2% from the prior quarter. Over 3 fiscal years it compounded at +1221.7% a year.

Context

  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 8 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +215386.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.74B+78396.2% QoQ
Last fiscal yearDec 2025
$6.8B+215386.7% YoY
LTMMar 2026
$1.74B+43733.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+110009.0%-100.0%-110109.0 pp
1 year+215386.7%-100.0%-215486.7 pp
3-year CAGR+1221.7%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
6.8B USD
Year-over-year change
+215386.7%
4-year CAGR
+612.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How MNPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +43733.9% is the highest of 11, against a peer median of +2.8%.
  • Over three fiscal years its annual growth of +1221.7% compares with a peer median of +8.2%.
MNPR Competitors
Selling, General & Admin for MNPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYMEZymeworks Inc.LTM Sep 2026$15.14B USD+24248.6%-5.7%5694.1%
MNPRMonopar Therapeutics Inc.LTM Mar 2026$1.74B USD+43733.9%+1221.7%—
ADCTADC Therapeutics S.A.LTM Mar 2026$82.03M USD+32.5%—103.6%
BCYCBicycle Therapeutics plcLTM Mar 2026$76.67M USD+0.6%+17.4%120.8%
XNCRXencor, Inc.LTM Jun 2026$65.29M USD+5.1%+10.3%62.2%
IMNMImmunome, Inc.LTM Sep 2026$64.15M USD+52.3%+47.5%—
MGNXMacroGenics, Inc.LTM Mar 2026$38.15M USD-27.9%-12.7%24.3%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$21.28M USD-23.4%-6.3%—
CMPXCompass Therapeutics, Inc.LTM Mar 2026$18.51M USD+10.2%+13.1%—
IPHAInnate Pharma S.A.FY2025€11M EUR-7.8%-8.7%394.7%
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$7.41M USD-56.6%+8.2%21.1%
Peer median (excluding MNPR) —+2.8%+8.2%103.6%

Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development6.49M7.59M5.6M13.01M9.9B
Selling, General & Admin2.63M2.95M3.23M3.16M6.8B
Operating Expenses9.13M10.54M8.83M16.16M16.7M
Depreciation & Amortization00000
EBITDA(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
EBITDA Margin—————
Operating Income(9.13M)(10.54M)(8.83M)(16.16M)(16.7M)
Operating Margin—————
Interest Income24.02K21.24K429.04K404.02K2.99M
Interest Expense00000
Other Income / Expenses24.02K21.24K429.04K575.3K2.99M
Income Before Tax(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
Net Margin—————
EPS (Basic)(0.73)(0.83)(0.58)(1.36)(1.85)
EPS (Diluted)(0.73)(0.83)(0.58)(1.36)(1.85)
Weighted Avg Shares12.47M12.72M14.51M11.44M7.41M
Weighted Avg Shares (Diluted)12.47M12.72M14.51M11.48M7.41M

Monopar Therapeutics Inc.

NASDAQ:MNPR

Intrinsic Alpha fair value

Locked

Current Price

$70.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.